Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Cholangiocarcinoma 3Glioblastoma 2Upper Tract Urothelial Carcinomas 1Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Papillomavirus Infections 1Oncogenic osteomalacia 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Melanoma 1Hypophosphatemia 1Hematologic Neoplasms 1Glioma 1Breast Neoplasms 1Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

infigratinib 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Upper Tract Urothelial Carcinomas × infigratinib × Clear all
NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated
39 enrolled 31 charts
Genitourinary

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡